CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 28 enrolled
Drug / intervention
LY900014 (SC) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03232983
NCT03232983Phase 1Completed
CompareCT.gov

Effect of Injection Site on the Relative and Absolute Bioavailability of Single Dose of LY900014 in Healthy Subjects

Eli Lilly and Company·interventional·Posted Jul 28, 2017·Updated Apr 30, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 (SC) and LY900014 (IV) for Diabetes Mellitus, Type 2. Completed, enrolled 28 participants across 1 site.

Detailed Summary

This study evaluates a new formulation of insulin lispro, LY900014, a drug that lowers blood sugar. It is administered by injection into the vein and under the skin of the abdomen, thigh and arm. The study will be conducted in healthy people to investigate the effect of different injection sites on the amount of insulin lispro in the bloodstream. Side effects and tolerability will be documented. The study will last for about 10 weeks for each participant, including screening and follow up. Screening is required within 28 days prior to entering the study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedJul 28, 2017
Enrollment StartAug 14, 2017
Primary CompletionNov 9, 2017
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 8.9 years ago

Interventions

LY900014 (SC)drug

Administered SC

LY900014 (IV)drug

Administered IV